Earnings Call Summary | Seer Inc(SEER.US) Q4 2023 Earnings Conference
Earnings Call Summary | Seer Inc(SEER.US) Q4 2023 Earnings Conference
The following is a summary of the Seer, Inc. (SEER) Q4 2023 Earnings Call Transcript:
以下是Seer, Inc.（SEER）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Seer reported a Q4 2023 revenue of $4.4 million, a 4% decrease from Q4 2022, primarily due to a decrease in lease revenue related to SP100 instruments.
The company's gross margin in Q4 2023 was 45.1% compared to 49.8% in Q4 2022.
Q4 net loss was $17.8 million compared to $22.5 million in Q4 2022.
Despite the Q4 decrease, Seer's total revenue for FY 2023 increased by 8%, rising from $15.5 million in 2022 to $16.7 million.
The net loss for the year was $86.3 million, less than the $93 million loss in 2022.
The company reported approximately $373.1 million in cash, cash equivalents, and investments at the end of 2023.
Seer報告稱，2023年第四季度收入爲440萬美元，比2022年第四季度下降4％，這主要是由於與 SP100 工具相關的租賃收入減少。
該公司在2023年第四季度的毛利率爲45.1％，而2022年第四季度的毛利率爲49.8％。
第四季度的淨虧損爲1,780萬美元，而2022年第四季度爲2,250萬美元。
儘管第四季度有所下降，但西爾2023財年的總收入增長了8％，從2022年的1,550萬美元增加到1,670萬美元。
該年度的淨虧損爲8,630萬美元，低於2022年的9,300萬美元虧損。
截至2023年底，該公司報告了約3.731億美元的現金、現金等價物和投資。
Business Progress:
業務進展：
A major part of Seer's revenue increase in 2023 is attributed to service revenue related to its STAC (Seer Technology Access Center).
The company managed to ship 23 SP100 instruments in 2023, for a cumulative total of 62 instruments shipped till the end of the year.
Key growth strategies for 2024 include driving evidence and publication, improving access, and promoting product innovation and applications.
Operational enhancements in 2023 included launching the Proteograph XT Assay Kit and enhancing the Proteograph Analysis Suite.
The company made its Protein Discovery Catalog of over 10,000 detectable proteins available to customers.
Seer expanded its Centers of Excellence programs with the addition of Panome Bio and also brought on board four new international distributors and partners.
2023年仙工智能收入增長的很大一部分歸因於與其STAC（仙工科技接入中心）相關的服務收入。
該公司在 2023 年成功出貨了 23 臺 SP100 儀器，到年底累計出貨了 62 臺儀器。
2024年的主要增長戰略包括推動證據和出版、改善可及性以及促進產品創新和應用。
2023 年的操作改進包括推出 Proteograph XT 檢測試劑盒和強化 Proteograph 分析套件。
該公司向客戶提供了包含超過10,000種可檢測蛋白質的蛋白質發現目錄。
Seer通過加入Panome Bio擴大了其卓越中心計劃，還吸引了四家新的國際分銷商和合作夥伴。
More details: Seer Inc IR
更多詳情： Seer Inc IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。